Llwytho...
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclopho...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Onco Targets Ther |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5189703/ https://ncbi.nlm.nih.gov/pubmed/28053548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S117007 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|